Sembragiline

Sembragiline
Clinical data
Other namesEVT-302; EVT302; RG-1577; RG1577; RO-4602522; RO4602522
Routes of
administration		Oral
Drug classReversible monoamine oxidase B (MAO-B) inhibitor
Identifiers
  • N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-5-oxopyrrolidin-3-yl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H19FN2O3
Molar mass342.370 g·mol−1
3D model (JSmol)
  • CC(=O)N[C@H]1CC(=O)N(C1)C2=CC=C(C=C2)OCC3=CC(=CC=C3)F
  • InChI=1S/C19H19FN2O3/c1-13(23)21-16-10-19(24)22(11-16)17-5-7-18(8-6-17)25-12-14-3-2-4-15(20)9-14/h2-9,16H,10-12H2,1H3,(H,21,23)/t16-/m0/s1
  • Key:VMAVCCUQTALHOB-INIZCTEOSA-N

Sembragiline (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names EVT-302, RG-1577, RO-4602522) is a selective and reversible monoamine oxidase B (MAO-B) inhibitor which is or was under development for the treatment of Alzheimer's disease. It was also under development for the treatment of smoking withdrawal, but development for this indication was discontinued. The drug is taken by mouth. Sembragiline is or was being developed by Roche and Evotec SE.

References

  1. 1 2 3 4 5 "Sembragiline". AdisInsight. 5 November 2023. Retrieved 24 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on Sembragiline with Synapse". Synapse. 22 February 2025. Retrieved 24 February 2025.
  3. 1 2 3 "Sembragiline". ALZFORUM. 20 November 2015. Retrieved 24 February 2025.
  4. 1 2 Lin P, Sun J, Cheng Q, Yang Y, Cordato D, Gao J (December 2021). "The Development of Pharmacological Therapies for Alzheimer's Disease". Neurology and Therapy. 10 (2): 609–626. doi:10.1007/s40120-021-00282-z. PMC 8571471. PMID 34532845. Sembragiline (also known as RO4602522, RG1577 and EVT302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor developed to treat AD. A PET study revealed almost complete inhibition of central MAO-B at an oral dose of 1 mg per day in AD patients; however, no cognitive benefits were detected after treatment [91].